The treatment and prognosis of patients with renal adenocarcinoma with solitary metastasis. 10 year survival results.
From 1969-1976, 25 patients with renal adenocarcinoma and solitary metastasis were treated and are now eligible for 10-14-year survival analysis. There were 17 men and 8 women, mean age 60 years, range 37-75 years. Twelve patients had focus in bone and 13 patients in other localizations: lungs 6, thyroid 3, flank 3, and epididymis 1. Sixteen out of twenty-five patients were treated with the radiotherapy 45-50 Gy in 23-25 fractions as the only treatment. The median survival was 4.3 years, the 5-year survival 36%, and the 10-year survival 16%. Women had 5- and 10-year survival rates of 76% and 38% respectively. Men had 5-year survival of 18% and 10-year survival of 12% (p = 0.05). There were no significant differences between the survival of patients with bone metastases and patients with soft tissue metastases. Three patients are living NED at 14 years. Seventeen of twenty-two patients died of progressive renal adenocarcinoma whereas 5/22 died from other causes. We conclude: It is possible to obtain long term survival greater than 10 years and maybe even cure in a fraction of these patients by aggressive treatment. Radiotherapy is a highly potential treatment modality giving the same or better results as those reported in the literature after extensive and disabling surgical resections. However, it cannot be excluded that the favorable prognosis for these patients merely reflects the natural clinical course of the disease in this specific subgroup.
D000230:Adenocarcinoma / Q000532:radiotherapy* / Q000628:therapy; D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000532:radiotherapy* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis